Loss of Vav2 proto-oncogene causes tachycardia and cardiovascular disease in mice

Molecular Biology of the Cell

Volumn 18, Issue 3, 2007, Pages 943-952

  Sauzeau, Vincent ^a   Jerkic, Mirjana ^a   López Novoa, José M ^a   Bustelo, Xosé R ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ACTIVATOR; ISOPROTEIN; PROTEIN VAV1; PROTEIN VAV2; PROTEIN VAV3; RAC PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY WALL; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE DISRUPTION; GENE LOCUS; GENETIC ASSOCIATION; HOMEOSTASIS; HYPERTENSION; KIDNEY DISEASE; KNOCKOUT GENE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTO ONCOGENE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TACHYCARDIA; VAV2 GENE;

ADRENAL GLANDS; ALDOSTERONE; ANIMALS; AORTA; ENDOTHELINS; GENE EXPRESSION REGULATION; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HEART VENTRICLES; HYPERTENSION; KIDNEY; KIDNEY FUNCTION TESTS; MICE; MICE, KNOCKOUT; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-VAV; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; TACHYCARDIA; VASOPRESSINS;

MAMMALIA; MUS;

EID: 33947115378     PISSN: 10591524     EISSN: None     Source Type: Journal    
DOI: 10.1091/mbc.E06-09-0877     Document Type: Article

References (25)

1. Beevers, G., Lip, G. Y., and O'Brien, E. (2001). ABC of hypertension: the pathophysiology of hypertension. BMJ 322, 912-916.
2. Bourbon, H. M. et al. (2002). A P-insertion screen identifying novel X-linked essential genes in Drosophila. Mech. Dev. 110, 71-83.
3. Bustelo, X. R. (2000). Regulatory and signaling properties of the Vav family. Mol. Cell. Biol. 20, 1461-1477.
4. Bustelo, X. R., Ledbetter, J. A., and Barbacid, M. (1992). Product of Vav proto-oncogene defines a new class of tyrosine protein kinase substrates. Nature 356, 68-71.
5. Carrasco, G. A., and Van de Kar, L. D. (2003). Neuroendocrine pharmacology of stress. Eur. J. Pharmacol. 463, 235-272.
6. Chevillard, C., Brown, N. L., Mathieu, M. N., Laliberte, F., and Worcel, M. (1988). Differential effects of oral trandolapril and enalapril on rat tissue angiotensin-converting enzyme. Eur. J. Pharmacol. 147, 23-28.
7. Couceiro, J. R., Martin-Bermudo, M. D., and Bustelo, X. R. (2005). Phylogenetic conservation of the regulatory and functional properties of the Vav oncoprotein family. Exp. Cell Res. 308, 364-380.
8. Doody, G. M., Bell, S. E., Vigorito, E., Clayton, E., McAdam, S., Tooze, R., Fernandez, C., Lee, I. J., and Turner, M. (2001). Signal transduction through Vav-2 participates in humoral immune responses and B cell maturation. Nat. Immunol. 2, 542-547.
9. Faccio, R., Teitelbaum, S. L., Fujikawa, K., Chappel, J., Zallone, A., Tybulewicz, V. L., Ross, F. P., and Swat, W. (2005). Vav3 regulates osteoclast function and bone mass. Nat Med. 11, 284-290.
10. Flores, O., Arevalo, M., Gallego, B., Hidalgo, F., Vidal, S., and Lopez-Novoa, J. M. (1998). Beneficial effect of the long-term treatment with the combination of an ACE inhibitor and a calcium channel blocker on renal injury in rats with 5/6 nephrectomy. Exp. Nephrol. 6, 39-49.
11. Fujikawa, K. et al. (2003). Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cells. J. Exp. Med. 198, 1595-1608.
12. Jerkic, M., Rivas-Elena, J. V., Prieto, M., Carron, R., Sanz-Rodriguez, F., Perez-Barriocanal, F., Rodriguez-Barbero, A., Bernabeu, C., and Lopez-Novoa, J. M. (2004). Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J. 18, 609-611.
13. Lenders, J. W., Eisenhofer, G., Mannelli, M., and Pacak, K. (2005). Phaeochromocytoma. Lancet 366, 665-675.
14. Lifton, R. P., Gharavi, A. G., and Geller, D. S. (2001). Molecular mechanisms of human hypertension. Cell 104, 545-556.
15. Margolis, B., Hu, P., Katzav, S., Li, W., Oliver, J. M., Ullrich, A., Weiss, A., and Schlessinger, J. (1992). Tyrosine phosphorylation of Vav proto-oncogene product containing SH2 domain and transcription factor motifs. Nature 356, 71-74.
16. Movilla, N., and Bustelo, X. R. (1999). Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol. Cell. Biol. 19, 7870-7885.
17. Norman, K. R., Fazzio, R. T., Mellem, J. E., Espelt, M. V., Strange, K., Beckerle, M. C., and Maricq, A. V. (2005). The Rho/Rac-family guanine nucleotide exchange factor VAV-1 regulates rhythmic behaviors in C. elegans. Cell 123, 119-132.
18. Palatini, P., Benetos, A., and Julius, S. (2006). Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs 66, 133-144.
19. Remuzzi, G., Perico, N., and Benigni, A. (2002). New therapeutics that antagonize endothelin: promises and frustrations. Nat. Rev. Drug Discov. 1, 986-1001.
20. Sauzeau, V., Sevilla, M. A., Rivas-Elena, J. V., de Alava, E., Montero, M. J., Lopez-Novoa, J. M., and Bustelo, X. R. (2006). Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction. Nat. Med. 12, 841-845.
21. Takahashi, N., and Smithies, O. (1999). Gene targeting approaches to analyzing hypertension. J. Am. Soc. Nephrol. 10, 1598-1605.
22. Tedford, K., Nitschke, L., Girkontaite, I., Charlesworth, A., Chan, G., Sakk, V., Barbacid, M., and Fischer, K. D. (2001). Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling. Nat. Immunol. 2, 548-555.
23. Turner, M., and Billadeau, D. D. (2002). VAV proteins as signal integrators for multi-subunit immune-recognition receptors. Nat. Rev. Immunol. 2, 476-486.
24. Tybulewicz, V. L., Ardouin, L., Prisco, A., and Reynolds, L. F. (2003). Vav 1, a key signal transducer downstream of the TCR. Immunol. Rev. 192, 42-52.
25. Valdivielso, J. M., Crespo, C., Alonso, J. R., Martinez-Salgado, C., Eleno, N., Arevalo, M., Perez-Barriocanal, F., and Lopez-Novoa, J. M. (2001). Renal ischemia in the rat stimulates glomerular nitric oxide synthesis. Am. J. Physiol. 280, R771-R779.